CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
21-169

Chemistry Review(s)

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA#: 21-169 CHEM.REVIEW # 3 REVIEW DATE: 30-OCT-00

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
Amendment	27-JUN-00	28-JUN-00	28-JUN-00
Amendment	19-JUL-00	20-JUL-00	20-JUL-00
Amendment	31-AUG-00	01-SEP-00	05-SEP-00

NAME & ADDRESS OF APPLICANT:

Janssen Pharmaceutica
1125 Trenton-Harbourton Road
Titusville, NJ 08560-0200

DRUG PRODUCT NAME

Proprietary: Reminyl (galantamine hydrobromide) Tablets
Nonproprietary/USAN: Galantamine hydrobromide
Code Name/#:
Chem.Type/Ther.Class: 1S/Acetylcholine Esterase Inhibitor

PHARMACOL.CATEGORY/INDICATION: AD

DOSAGE FORM: Tablets
STRENGTHS: 4 mg, 8 mg, 12 mg (eq to base)
ROUTE OF ADMINISTRATION: Oral
DISPENSED: XXXXX Rx_____OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-ef][2]-benzodiazepin-6-ol hydrobromide
$C_{17}H_{22}BrNO_3$; Molecular Weight: 368.27;
CAS #: 1953-04-0 (hydrobromide); 357-70-0 (base)



SUPPORTING DOCUMENTS: DMF[ ] galantamine HBr)
RELATED DOCUMENTS:
REMARKS/COMMENTS: Reply to IR Letter of 29-JUN-00 and to AE letter of 29-JUL-00. Most of the concerns addressed in the IR letter have been addressed and the DMF deficiencies corrected. It appears that USAN accepted Reminyl trademark as a catch-them-all name for both galantamine and galantamine hydrobromide. See the copy of E-mail attached. The sponsor agrees to use the name Reminyl only in conjunction with the galantamine hydrobromide. Facilities acceptable as of 21-JUL-00. Copy of EER attached.

CONCLUSIONS & RECOMMENDATIONS : Recommend the approval of NDA 21-169.

cc:
Orig. NDA 21-169
HFD-120
HFD-120/WJRzeszotarski
HFD-120/Fanari
HFD-120/MEGuzewska
R/D Init by:MEG

/S/ 1/16/01

W. Janusz Rzeszotarski, Ph.D., Chemist

Redacted 8

pages of trade

secret and/or

confidential

commercial

information

FANARI

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

JUN 29 2000

NDA#: 21-169 **CHEM.REVIEW #** 2 **REVIEW DATE:** 29-JUN-00

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL	25-MAY-00	26-MAY-00	26-MAY-00

NAME & ADDRESS OF APPLICANT: Janssen Pharmaceutica
1125 Trenton-Harbourton Road
Titusville, NJ 08560-0200

DRUG PRODUCT NAME
Proprietary: Reminyl (galantamine hydrobromide) Tablets
Nonproprietary/USAN: Galantamine hydrobromide
Code Name/#:
Chem.Type/Ther.Class: 1S/Acetocholine Esterase Inhibitor

PHARMACOL.CATEGORY/INDICATION: AD

DOSAGE FORM: Tablets
STRENGTHS: 4 mg, 8 mg, 12 mg (eq to base)
ROUTE OF ADMINISTRATION: Oral
DISPENSED: XXXXX Rx_____OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-ef][2]-benzodiazepin-6-ol hydrobromide
$C_{17}H_{22}BrNO_3$; Molecular Weight: 368.27;
CAS #: 1953-04-0 (hydrobromide); 357-70-0 (base)



SUPPORTING DOCUMENTS: DMF( )galantamine HBr)
RELATED DOCUMENTS:
REMARKS/COMMENTS: Reply to IR Letter of 21-MAR-00. Most of the concerns addressed in the IR letter have been addressed except for the API and drug product specifications which have to be consolidated and edited to reflect the actual analytical findings in the batches supporting the clinical studies.

CONCLUSIONS & RECOMMENDATIONS: Recommend the NDA 21-169 approvable subject to the resolution of remaining specification issues and an acceptable EER. Draft IR letter attached. The most recent copy of EER attached and the E-mail exchanges pertinent to timely completion of inspections by the OC.

cc:
Orig. NDA 21-169
HFD-120
HFD-120/WJRzeszotarski
HFD-120/Fanari
HFD-120/MEGuzewska
R/D Init by:MEG 6/29/00

/S/
W. Janusz Rzeszotarski, Ph.D., Chemist

Redacted 10

pages of trade

secret and/or

confidential

commercial

information

Malandrucco

DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls MAR 21 2000

NDA#: 21-169 **CHEM.REVIEW #** 1 **REVIEW DATE:** 21-MAR-00

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL	29-SEP-99	29-SEP-99	04-OCT-99

NAME & ADDRESS OF APPLICANT: Janssen Pharmaceutica
1125 Trenton-Harbourton Road
Titusville, NJ 08560-0200

DRUG PRODUCT NAME
Proprietary: Reminyl (galantamine) Tablets
Nonproprietary/USAN: Galantamine hydrobromide
Code Name/#:
Chem.Type/Ther.Class: 1S/Acetocholine Esterase Inhibitor

PHARMACOL.CATEGORY/INDICATION: AD

DOSAGE FORM: Tablets
STRENGTHS: 4 mg, 8 mg, 12 mg (eq to base)
ROUTE OF ADMINISTRATION: Oral
DISPENSED: XXXXX Rx_____OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-ef][2]-benzodiazepin-6-ol hydrobromide
$C_{17}H_{22}BrNO_3$; Molecular Weight: 368.27;
CAS #: 1953-04-0 (hydrobromide); 357-70-0 (base)



SUPPORTING DOCUMENTS: DMF[ ](galantamine HBr)
RELATED DOCUMENTS:
REMARKS/COMMENTS: Galantamine is a tertiary alkaloid that has been isolated from the bulbs of the Caucasian snowdrop Galanthus woronii (Proskurina and Yakovleva, 1952), the common snowdrop Gananthus nivalis (Boit, 1954), various species of Narcissus (Boit et al., 1957) and other plant sources. The galantamine hydrobromide, used to make the tablets described in present application, is of plant origin, produced from the extract from the bulbs of Narcissus pseudonarcissus (daffodil) of the varieties "Carlton" and "Tee Follies". The sponsor amended the IND to provide for the synthetic galantamine HBr but has not included that source of API in the NDA submitted. All Reminyl tablet formulations have the same qualitative and dose-proportional quantitative tablet core composition. Size, color and embossing differentiate tablets of different strength from each other. The application does not provide the acceptance methods for the API, covered by the DMF[ ] and the MV is made impossible by creation of individual methods, in name, for the each strength. Other deficiencies are also listed in the IR letter (see attached).
CONCLUSIONS & RECOMMENDATIONS: Fact that in the present form the DMF[ ] does not support the NDA 21-169, and the improper organization of MV documents makes MV impossible renders the NDA not-approvable. Draft IR letter attached. The most recent copy of EER attached.

cc:
Orig. NDA 21-169
HFD-120
HFD-120/WJRzeszotarski
HFD-120/MMalandrucco
HFD-120/MEGuzewska 3/21/00
R/D Init by:MEG

/S/
W. Janusz Rzeszotarski, Ph.D., Chemist

filename: E:\msword\n21169r.001.doc

Redacted 46

pages of trade

secret and/or

confidential

commercial

information

Malandra

MAR 16 2000

DMF REVIEW COVER FORM

DMF: DMF Type: II

Title: **Galantamine Hydrobromide Drug Substance**

1. CHEM REVIEW # 1 2. REVIEW DATE: 16-MAR-2000

3. ITEM REVIEWED

A. IDENTIFICATION

USAN	applied for
Ingredient Dictionary name	galantamine hydrobromide (USAN listing)
Name	Galantamin, Galanthine, Nivalin, Nivalina, Lycoremin, Karatonon
code	R113675/073575
Chemical names	([4aS-(4aα,6R,8aS)] -4a,5,9,10,11,12-hexahydro-3 -methoxy-11-methyl-6*H*- benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide (USAN appl.) 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide (Merck Index) ([4aS -(4aα,6β,8aR*)] -4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide (CA Service)
CAS number, if available	1953-04-0 (hydrobromide) 357-70-0 (base)

B. LOCATION IN DMF

Type of Submission	Date of Submission	Location of Information
Original		



4. PREVIOUS DOCUMENTS

Type of Document	Date of Document	Description

5. NAME & ADDRESS OF DMF HOLDER AND REPRESENTATIVE(S):

NAME:
ADDRESS:

REPRESENTATIVE or U.S. AGENT (if applicable):
NAME:
ADDRESS:

CONTACT PERSON'S
ADDRESS:
TELEPHONE NUMBER:

6. DMF REFERENCED FOR:

NDA\ANDA\AADA\IND: NDA 21-169
PRIMARY DMF (as needed)
APPLICANT NAME: Janssen Research Foundation
LOA DATE: 29-SEP-99
DRUG PRODUCT NAME: REMINYL (galantamine) Tablets
DOSAGE FORM: Tablets CODE:XXX
STRENGTH: 4 mg, 8 mg & 12 mg

ROUTE OF ADMINISTRATION: Oral CODE:XXX

7. SUPPORTING DOCUMENTS:

8. CURRENT STATUS OF DMF:
DATE OF LAST UPDATE OF DMF: N/A
DATE OF MOST RECENT LIST OF COMPANIES FOR WHICH LOA's HAVE BEEN PROVIDED:
Janssen Pharmaceutica; 29-SEP-99

9. CONSULTS: None

10. COMMENTS: [redacted] and are neither supported by the batch analysis nor backed by the patient exposure during the clinical trials. Minor other deficiencies (see the Draft Deficiency Letter)

11. CONCLUSION: In its present form the DMF is deficient and does not support the NDA 21-169.

cc:
Original DMF
HFD-/IND/NDA # 21-169 Division File
HFD-120/Divison Director
HFD-120/MMalandrucco
HFD-120/MGuzewska
HFD-120/WJRzeszotarski 5/16/00

Drafted by: drafter's initials/date
Initaled by:
final:

/S/ 16MAR2000

DMF REVIEW

Redacted 40

pages of trade

secret and/or

confidential

commercial

information

ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Application: NDA 21169/000
Stamp: 29-SEP-1999
Regulatory Due: 28-FEB-2001
Applicant: JANSSEN RES FDN
11250 TRENTON HARBOURTON RD
TITUSVILLE, NJ 085600200
Priority: 1S
Org Code: 120

Action Goal:
District Goal: 30-MAY-2000
Brand Name: REMINYL(GALANTHAMINE)4MG/8MG/12MG TABLET
Estab. Name:
Generic Name: GALANTHAMINE

Dosage Form: (TABLET)
Strength: 4 MG, 8 MG, 12 MG

Application Comment: PRODUCT SPECIFIC INSPECTION (on 30-NOV-1999 by W. RZESZOTARSKI (HFD-120) 301-594-2850)

FDA Contacts: M. FANARI (HFD-120) 301-594-5526 , Project Manager
W. RZESZOTARSKI (HFD-120) 301-594-2850 , Review Chemist
M. GUZEWSKA (HFD-120) 301-594-5571 , Team Leader

Overall Recommendation: ACCEPTABLE on 21-JUL-2000 by P. ALCOCK (HFD-324) 301-827-0062

Establishment: 9614770
JANSSEN CILAG SPA
LATINA, , IT

DMF No: AADA:
Responsibilities: FINISHED DOSAGE MANUFACTURER
Profile: TCM OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	PS			EGASM
ASSIGNED INSPECTION	03-DEC-1999	PS			EGASM
INSPECTION SCHEDULED	20-JUN-2000		06-JUL-2000		IRIVERA
INSPECTION PERFORMED	21-JUL-2000		06-JUL-2000		ALCOCKP
DO RECOMMENDATION	21-JUL-2000			ACCEPTABLE ADEQUATE FIRM RESPONSE	ALCOCKP
BASED ON REVIEW OF FIRM'S RESPONSE AND FDA-483 - INVESTIGATOR RECOMMENDATION HAS NOT BEEN SENT TO HFD-322 OR DEIO AS OF YET AND COULD NOT BE LOCATED. UF 7-29-00					
OC RECOMMENDATION	21-JUL-2000			ACCEPTABLE DISTRICT RECOMMENDATION	ALCOCKP
BASED ON REVIEW OF FDA-483 AND FIRM'S RESPONSE ONLY - REVIEW OF EIR TO FOLLOW UPON RECEIPT TO HFD-322					

Establishment: 2650104
JANSSEN ORTHO INC
STATE RD 933 KM 0.1 MAMEY WARD
GURABO, PR 00658

DMF No: AADA:
Responsibilities: FINISHED DOSAGE PACKAGER
Profile: TCM OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
OC RECOMMENDATION	01-DEC-1999			ACCEPTABLE BASED ON PROFILE	FERGUSONS

Establishment: 2242843
JANSSEN PHARMACEUTICA INC

1125 TRENTON HARBOURTON RD
TITUSVILLE, NJ 08560

DMF No: AADA:

Responsibilities: FINISHED DOSAGE RELEASE TESTER

Profile: CTL OAI Status: NONE

Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			FERGUSONS
DO RECOMMENDATION	01-FEB-2000			ACCEPTABLE BASED ON FILE REVIEW	RBROWN4
OC RECOMMENDATION	01-FEB-2000			ACCEPTABLE DISTRICT RECOMMENDATION	DAMBROGIOJ

Establishment: 9610034

JANSSEN PHARMACEUTICA NV
B-2440
GEEL, , BE

DMF No: AADA:

Responsibilities: DRUG SUBSTANCE MANUFACTURER

Profile: CSN OAI Status: NONE

Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			EGASM
ASSIGNED INSPECTION	03-DEC-1999	GMP			EGASM
INSPECTION SCHEDULED	09-APR-2000		08-MAY-2000		IRIVERA
INSPECTION PERFORMED	12-MAY-2000		05-MAY-2000		EGASM
DO RECOMMENDATION	18-JUL-2000			ACCEPTABLE INSPECTION	EGASM
OC RECOMMENDATION	18-JUL-2000			ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: DA:

Responsibilities:

Profile: CEX OAI Status: NONE

Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	04-JAN-2000	PS			EGASM
ASSIGNED INSPECTION	04-JAN-2000	PS			EGASM
INSPECTION SCHEDULED	24-FEB-2000		10-APR-2000		IRIVERA
INSPECTION PERFORMED	10-APR-2000		10-APR-2000		EGASM
DO RECOMMENDATION	22-JUN-2000			ACCEPTABLE INSPECTION	EGASM
OC RECOMMENDATION	22-JUN-2000			ACCEPTABLE	EGASM

DISTRICT RECOMMENDATION

Establishment:

DMF No: AADA:
Responsibilities:
Profile: CRU OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			EGASM
ASSIGNED INSPECTION	22-DEC-1999	GMP			EGASM
INSPECTION SCHEDULED	09-APR-2000		12-MAY-2000		IRIVERA
INSPECTION PERFORMED	15-MAY-2000		11-MAY-2000		EGASM
DO RECOMMENDATION	18-JUL-2000			ACCEPTABLE INSPECTION	EGASM
OC RECOMMENDATION	18-JUL-2000			ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: AADA:
Responsibilities:
Profile: TCM OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			FERGUSONS
DO RECOMMENDATION	28-DEC-1999			ACCEPTABLE BASED ON FILE REVIEW	DPAGANO
PHI-DO CONDUCTED AN INSPECTION 9/99, CLASSED NAI.					
OC RECOMMENDATION	29-DEC-1999			ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: AADA:
Responsibilities:
Profile: TCM OAI Status: NONE
Estab. Comment: ESTABLISHMENT CHANGED NAME TO EFF. 2/9/99; CFN AND LABELER CODE REMAINS THE SAME. (on 01-DEC-1999 by M. TORRES IRIZARRY (HFR-SE550) 787-729-6728)

ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			FERGUSONS
ASSIGNED INSPECTION	01-DEC-1999	GMP			MTORRES
INSPECTION SCHEDULED	14-DEC-1999		15-FEB-2000		MTORRES
INSPECTION PERFORMED	27-JAN-2000		21-JAN-2000		MTORRES
NEW NAME/OWNERSHIP FOR THIS FIRM: CFN					- SAME
DO RECOMMENDATION	27-JAN-2000			ACCEPTABLE	MTORRES
OC RECOMMENDATION	28-JAN-2000			ACCEPTABLE INSPECTION DISTRICT RECOMMENDATION	FERGUSONS

ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Application: NDA 21169/000
Stamp: 29-SEP-1999
Regulatory Due: 29-JUL-2000
Applicant: JANSSEN RES FDN
1125 TRENTON-HARBOURTON RD
TITUSVILLE, NJ 085600200
Priority: 1S
Org Code: 120

Action Goal:
District Goal: 30-MAY-2000
Brand Name: REMINYL(GALANTHAMINE)4MG/8MG/12MG TABLET
Estab. Name:
Generic Name: GALANTHAMINE

Dosage Form: (TABLET)
Strength: 4 MG, 8 MG, 12 MG

Application Comment: PRODUCT SPECIFIC INSPECTION (on 30-NOV-1999 by W. RZESZOTARSKI (HFD-120) 301-594-2850)

FDA Contacts: M. FANARI (HFD-120) 301-594-2850 , Project Manager
W. RZESZOTARSKI (HFD-120) 301-594-2850 , Review Chemist
M. GUZEWSKA (HFD-120) 301-594-5571 , Team Leader

Overall Recommendation: ACCEPTABLE on 21-JUL-2000 by P. ALCOCK (HFD-324) 301-827-0062

Establishment: 9614770
JANSSEN CILAG SPA
LATINA, , IT

DMF No:
AADA:
Responsibilities: FINISHED DOSAGE MANUFACTURER
Profile: TCM
OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	PS			EGASM
ASSIGNED INSPECTION	03-DEC-1999	PS			EGASM
INSPECTION SCHEDULED	20-JUN-2000		06-JUL-2000		IRIVERA
INSPECTION PERFORMED	21-JUL-2000		06-JUL-2000		ALCOCKP
DO RECOMMENDATION	21-JUL-2000			ACCEPTABLE	ALCOCKP
				ADEQUATE FIRM RESPONSE	
BASED ON REVIEW OF FIRM'S RESPONSE AND FDA-483 - INVESTIGATOR RECOMMENDATION HAS NOT BEEN SENT TO HFD-322 OR DEIO AS OF YET AND COULD NOT BE LOCATED. UF 7-29-00					
OC RECOMMENDATION	21-JUL-2000			ACCEPTABLE	ALCOCKP
				DISTRICT RECOMMENDATION	
BASED ON REVIEW OF FDA-483 AND FIRM'S RESPONSE ONLY - REVIEW OF EIR TO FOLLOW UPON RECEIPT TO HFD-322					

Establishment: 2242843
JANSSEN PHARMACEUTICA INC
1125 TRENTON HARBOURTON RD
TITUSVILLE, NJ 08560

DMF No:
AADA:
Responsibilities: FINISHED DOSAGE RELEASE TESTER
Profile: CTL
OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			FERGUSONS
DO RECOMMENDATION	01-FEB-2000			ACCEPTABLE	RBROWN4
				BASED ON FILE REVIEW	
OC RECOMMENDATION	01-FEB-2000			ACCEPTABLE	DAMBROGIOJ

DISTRICT RECOMMENDATION

Establishment: 9610034
JANSSEN PHARMACEUTICA NV
B-2440
GEEL, , BE
DMF No: AADA:
Responsibilities: DRUG SUBSTANCE MANUFACTURER
Profile: CSN OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			EGASM
ASSIGNED INSPECTION	03-DEC-1999	GMP			EGASM
INSPECTION SCHEDULED	09-APR-2000		08-MAY-2000		IRIVERA
INSPECTION PERFORMED	12-MAY-2000		05-MAY-2000		EGASM
DO RECOMMENDATION	18-JUL-2000			ACCEPTABLE INSPECTION	EGASM
OC RECOMMENDATION	18-JUL-2000			ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: AADA:
Responsibilities:
Profile: TCM OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
OC RECOMMENDATION	01-DEC-1999			ACCEPTABLE BASED ON PROFILE	FERGUSONS

Establishment:

DMF No: AADA:
Responsibilities:
Profile: CEX OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	04-JAN-2000	PS			EGASM
ASSIGNED INSPECTION	04-JAN-2000	PS			EGASM
INSPECTION SCHEDULED	24-FEB-2000		10-APR-2000		IRIVERA
INSPECTION PERFORMED	10-APR-2000		10-APR-2000		EGASM
DO RECOMMENDATION	22-JUN-2000			ACCEPTABLE	EGASM

OC RECOMMENDATION	22-JUN-2000	INSPECTION ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: AADA:
Responsibilities:
Profile: CRU OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			EGASM
ASSIGNED INSPECTION	22-DEC-1999	GMP			EGASM
INSPECTION SCHEDULED	09-APR-2000		12-MAY-2000		IRIVERA
INSPECTION PERFORMED	15-MAY-2000		11-MAY-2000		EGASM
DO RECOMMENDATION	18-JUL-2000			ACCEPTABLE	EGASM
OC RECOMMENDATION	18-JUL-2000			INSPECTION ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: AADA:
Responsibilities:
Profile: TCM OAI Status: NONE
Estab. Comment:

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			FERGUSONS
DO RECOMMENDATION	28-DEC-1999			ACCEPTABLE BASED ON FILE REVIEW	DPAGANO
PHI-DO CONDUCTED AN INSPECTION 9/99, CLASSED NAI.					
OC RECOMMENDATION	29-DEC-1999			ACCEPTABLE DISTRICT RECOMMENDATION	EGASM

Establishment:

DMF No: AADA:
Responsibilities:
Profile: TCM OAI Status: NONE
Estab. Comment: ESTABLISHMENT CHANGED NAME TO
EFF. 2/9/99; CFN AND LABELER CODE REMAINS THE
SAME. (on 01-DEC-1999 by M. TORRES IRIZARRY (HFR-SE550) 787-729-

6728)

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO OC	30-NOV-1999				RZESZOTARS
SUBMITTED TO DO	01-DEC-1999	GMP			FERGUSONS
ASSIGNED INSPECTION	01-DEC-1999	GMP			MTORRES
INSPECTION SCHEDULED	14-DEC-1999		15-FEB-2000		MTORRES
INSPECTION PERFORMED	27-JAN-2000		21-JAN-2000		MTORRES
NEW NAME/OWNERSHIP FOR THIS FIRM: CFN					SAME
DO RECOMMENDATION	27-JAN-2000			ACCEPTABLE	MTORRES
OC RECOMMENDATION	28-JAN-2000			INSPECTION ACCEPTABLE DISTRICT RECOMMENDATION	FERGUSONS

APPEARS THIS WAY
ON ORIGINAL